← Back to Search

Amifostine to Prevent Side Effects in Small Cell Lung Cancer Treatment

Phase 2

Waitlist Available

Research Sponsored by University of Florida

Eligibility Criteria Checklist

Specific guidelines that determine who can or cannot participate in a clinical trial

Must have

Performance status ECOG 0-1

Histologically confirmed limited stage small cell lung cancer

Timeline

Screening 3 weeks

Treatment Varies

Follow Up up to 5 years

Awards & highlights

Study Summary

This trial is studying how well amifostine works in preventing side effects in patients with small cell lung cancer who are receiving chemotherapy and radiation therapy.

Who is the study for?

This trial is for adults over 18 with limited-stage small cell lung cancer. Participants must have normal blood counts, no active infections, and functioning liver and kidneys. They cannot be pregnant or nursing and must use effective contraception. Prior malignancies are mostly excluded except certain skin cancers or cervical carcinoma in situ.Check my eligibility

What is being tested?

The study is testing the drug Amifostine to see if it can prevent side effects in patients undergoing chemotherapy and radiation therapy for small cell lung cancer. This phase II trial aims to protect normal cells while tumor cells are targeted by treatments.See study design

What are the potential side effects?

Amifostine may cause side effects such as nausea, vomiting, low blood pressure, allergic reactions, dizziness, and a feeling of warmth or flushing.

Eligibility Criteria

Inclusion Criteria

You may be eligible if you check “Yes” for the criteria below

Select...

I am fully active or can carry out light work.

Select...

My lung cancer is confirmed to be small cell and in an early stage.

Select...

I am over 18 years old.

Select...

My creatinine level is below 1.5 mg/dL.

Select...

My liver function tests are within normal limits.

Timeline

Screening ~ 3 weeks3 visits

Treatment ~ Varies

Follow Up ~ up to 5 years

Screening ~ 3 weeks

Treatment ~ Varies

Follow Up ~up to 5 years

This trial's timeline: 3 weeks for screening, Varies for treatment, and up to 5 years for reporting.

Treatment Details

0 / 5Eligibility criteria met

Find a Location

Who is running the clinical trial?

University of FloridaLead Sponsor

1,340 Previous Clinical Trials

715,676 Total Patients Enrolled

Dean L. McCarley, MDStudy ChairVeterans Affairs Medical Center - Gainesville

Media Library

Treatment Clinical Trial Eligibility Overview. Trial Name: NCT00003583 — Phase 2

Lung Cancer Clinical Trial 2023: Treatment Highlights & Side Effects. Trial Name: NCT00003583 — Phase 2

Treatment 2023 Treatment Timeline for Medical Study. Trial Name: NCT00003583 — Phase 2

Frequently Asked Questions

These questions and answers are submitted by anonymous patients, and have not been verified by our internal team.

Is recruitment presently ongoing for this research endeavor?

"According to clinicaltrials.gov, this analysis is no longer enrolling participants; its post date was June 1st 1997 and it has not been revised since December 3rd 2013. However, there are presently 1770 other trials open for enrollment at present."

Answered by AI

Has this course of therapy been validated by the Food and Drug Administration?

"With a score of 2, there is evidence to suggest that this treatment has some level of safety according to our team at Power. However, Phase 2 trials do not have any data supporting efficacy as yet."

Answered by AI

Recent research and studies

clinicaltrials.govStudy

Amifostine to Prevent Side Effects in Patients Who Are Receiving Chemotherapy and Radiation Therapy for Limited-Stage Small Cell Lung Cancer

1997. "Amifostine to Prevent Side Effects in Patients Who Are Receiving Chemotherapy and Radiation Therapy for Limited-Stage Small Cell Lung Cancer". ClinicalTrials.gov. https://clinicaltrials.gov/ct2/show/NCT00003583.

All > Lung > Sclc